Analyst Price Target is $6.00
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for HTG Molecular Diagnostics in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a ∞ upside from the last price of $0.00.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in HTG Molecular Diagnostics. This Buy consensus rating has held steady for over two years.
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
Read More